Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) FCF Margin (2021 - 2024)

Allogene Therapeutics (ALLO) has disclosed FCF Margin for 4 consecutive years, with 254122.73% as the latest value for Q1 2024.

  • Quarterly FCF Margin fell 2854273.0% to 254122.73% in Q1 2024 from the year-ago period, while the trailing twelve-month figure was 913609.09% through Dec 2024, down 66176804.0% year-over-year, with the annual reading at 913609.09% for FY2024, 66176804.0% down from the prior year.
  • FCF Margin hit 254122.73% in Q1 2024 for Allogene Therapeutics, up from 256609.52% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 61.03% in Q4 2021 to a low of 282477.27% in Q2 2023.
  • Historically, FCF Margin has averaged 165115.97% across 4 years, with a median of 179843.59% in 2022.
  • Biggest YoY gain for FCF Margin was 1415980bps in 2022; the steepest drop was -22791974bps in 2022.
  • Year by year, FCF Margin stood at 61.03% in 2021, then crashed by -373437bps to 227980.77% in 2022, then dropped by -13bps to 256609.52% in 2023, then rose by 1bps to 254122.73% in 2024.
  • Business Quant data shows FCF Margin for ALLO at 254122.73% in Q1 2024, 256609.52% in Q4 2023, and 252463.64% in Q3 2023.